Ribavirin Treatment IND
Executive Summary
Top FDA officials, including Commissioner Young, met with ICN's outside counsel on Dec. 1. ICN said the company has not yet filed a third Treatment IND request for the anti-viral agent. The previous two were rejected by FDA ("The Pink Sheet" Sept. 7, 1987, p. 11). ICN has developed a protocol for a U.S. trial, which is under review at FDA. A Canadian protocol has been approved, and the study is expected to begin in that country "imminently," according to ICN....
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.